TwinStrand Biosciences has closed a $50 million Series B financing led by Section 32, with participation from new investors Soleus Capital, Janus Henderson Investors, and existing investors Madrona Venture Group, Ridgeback Capital, and Alexandria Venture Investments, among others.

TwinStrand's biochemistry and software-based solution enables researchers and clinicians to detect genetic 'needles in a haystack.' By identifying ultra-low frequency DNA mutations with a resolution 10,000-fold greater than conventional tools on the market, TwinStrand enables detection, quantification, and characterization of variants that were previously undetectable.